Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 12 member 7 (SLC12A7), commonly known as KCC4, is a protein that mediates electroneutral potassium-chloride cotransport across the plasma membrane in a 1:1 stoichiometry, important for maintaining potassium and chloride ion homeostasis within various tissues including kidney, inner ear, nervous system, and heart[1][2][3]. KCC4 is activated by cell swelling and is crucial for processes such as basolateral chloride extrusion in the kidney, acid-base metabolism, survival of cochlear hair cells, and maintaining organ function in the inner ear[1][3][4]. Mutations affecting KCC4 function are implicated in renal tubular acidosis and can contribute to electrolyte disturbances. While related cation-chloride cotransporters are clinically targeted by diuretic drugs, there are currently no approved drugs known to specifically modulate KCC4/SLC12A7[1][4].
For hypothetical drugs: Inhibition or modulation of potassium-chloride cotransport activity, affecting cellular ion homeostasis and volume regulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 12 member 7 (SLC12A7).